#WW IVI RU TRIAL#
Leaning on his experience from the Hepatitis A vaccine trial conducted in Thailand, he shared that Thailand enrolled 40,000 high school children in a study to prove that a Hepatitis A vaccine was safe and efficacious but the country failed to benefit from the vaccine as they could not afford it. “We use our expertise to engage in technology transfers so that companies like Incepta Pharmaceuticals in Bangladesh or Biovac in South Africa, will be able to manufacture a cholera vaccine that has the same characteristics as the vaccine manufactured by EuBiologics in Korea.” “IVI’s approach is to publish a study rather than patent the technology so we operate on a non-profit basis which is very different from pharmaceutical companies which need to recover their investment,” said Kim.
Although IVI is not directly affected by this issue, Kim still weighed in on the matter. Alternatively, a benefit-sharing arrangement can be integrated into purchase agreements such as the donation of products outside the vaccine manufacturer’s territories or subcontracting, licensing, or technology transfer incentivizes to increase the production of the vaccine. The draft of the treaty has not yet been finalized but the P-ABS of the pandemic treaty is expected to follow a framework that would grant access to 10-20 percent of real-time pandemic vaccine production to WHO to support the vaccine’s equitable distribution. However, due to the clause regarding pathogen access and benefit-sharing (P-ABS), some countries are skeptical of signing on to this treaty. The UN High-Level Meeting on pandemic prevention, preparedness, and response (PPPR) will soon be convened on September 20 to discuss PPPR equity through governance and capacity building. “We train participants on the epidemiology of different diseases and the vaccine manufacturing requirements from a laboratory, clinical, regulatory, and implementation perspective, with a focus on international standards.
“The course might have started as a way to train some of the International Vaccine Institute’s (IVI) collaborators in the basics of vaccinology but it has now evolved into a much more comprehensive course 22 years later,” said Kim. Jerome Kim spoke about the evolution of the program and other pressing issues facing vaccine developers such as the WHO Pandemic Treaty, climate change-related issues, and immune bridging studies. With the IVI opening its doors for the 22nd International Vaccinology Course on Monday, Dr. Jerome Kim speaks about striking the right balance between vaccine sovereignty and the joint global response with the WHO Pandemic Treaty in an interview on Monday at the IVI headquarters in Seoul. Jerome Kim, noted that the treaty is not perfect and will likely follow the same learning curve as COVAX. Referencing the COVAX initiative, which also fell prey to many criticisms for failing to deliver Covid-19 vaccines quickly, the Director General of the International Vaccine Institute (IVI), Dr. However, the WHO Pandemic Treaty which is carded to be further discussed next week in a UN High Level Meeting, has drawn the attention of Korean vaccine manufacturers due to a contentious clause regarding benefit sharing based on a joint global response in pandemics.
0 kommentar(er)
